TrialCancer medicine2017

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Hiroshi Ishiguro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.